[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG156692A1 - Aqueous ophthalmic suspension of crystalline rebamipide - Google Patents

Aqueous ophthalmic suspension of crystalline rebamipide

Info

Publication number
SG156692A1
SG156692A1 SG200907285-1A SG2009072851A SG156692A1 SG 156692 A1 SG156692 A1 SG 156692A1 SG 2009072851 A SG2009072851 A SG 2009072851A SG 156692 A1 SG156692 A1 SG 156692A1
Authority
SG
Singapore
Prior art keywords
rebamipide
aqueous
aqueous ophthalmic
ophthalmic suspension
crystalline
Prior art date
Application number
SG200907285-1A
Other languages
English (en)
Inventor
Takakuni Matsuda
Shogo Hiraoka
Yuso Tomohira
Shinichi Ishikawa
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of SG156692A1 publication Critical patent/SG156692A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG200907285-1A 2004-11-15 2005-11-11 Aqueous ophthalmic suspension of crystalline rebamipide SG156692A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004330140 2004-11-15

Publications (1)

Publication Number Publication Date
SG156692A1 true SG156692A1 (en) 2009-11-26

Family

ID=36336674

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200907285-1A SG156692A1 (en) 2004-11-15 2005-11-11 Aqueous ophthalmic suspension of crystalline rebamipide

Country Status (16)

Country Link
US (2) US9211254B2 (ko)
EP (1) EP1812000A4 (ko)
JP (3) JP4934587B2 (ko)
KR (1) KR101271959B1 (ko)
CN (1) CN100594901C (ko)
AR (2) AR052779A1 (ko)
AU (1) AU2005302908B2 (ko)
BR (1) BRPI0518928A2 (ko)
CA (1) CA2584017C (ko)
HK (1) HK1112718A1 (ko)
MX (1) MX2007005782A (ko)
MY (1) MY152867A (ko)
RU (1) RU2398585C2 (ko)
SG (1) SG156692A1 (ko)
TW (1) TWI363626B (ko)
WO (1) WO2006052018A1 (ko)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200808375A (en) * 2006-05-12 2008-02-16 Otsuka Pharma Co Ltd Hydrogel suspension and manufacturing process thereof
TWI415629B (zh) * 2006-10-26 2013-11-21 Otsuka Pharma Co Ltd 含有瑞巴匹特之水性醫藥懸浮物及其製造方法
WO2008074853A1 (en) * 2006-12-21 2008-06-26 Novartis Ag Ophthalmic rebamipide solution
BRPI0915427A2 (pt) * 2008-06-19 2015-11-03 Otsuka Pharma Co Ltd composição farmacêutica
US20100247666A1 (en) * 2009-03-24 2010-09-30 Macleod Steven K Method for Preparing Suspensions of Low-Solubility Materials
US9775802B2 (en) 2009-03-24 2017-10-03 Bausch & Lomb Incorporated Method for preparing suspensions of low-solubility materials
US20140010882A1 (en) * 2011-03-24 2014-01-09 Takakuni Matsuda Pharmaceutical composition for treating a disease in the oral cavity comprising rebamipide
TW201322982A (zh) * 2011-11-01 2013-06-16 Otsuka Pharma Co Ltd 用於治療前眼疾病之藥劑，該藥劑包含瑞巴派特及眼淚保持劑
SA113340675B1 (ar) * 2012-06-26 2015-08-16 استيش. كو.، ليمتد أدوية ريباميبايد تحضيرية جديدة، طريقة تحضيرها واستخدامها
KR101692578B1 (ko) 2013-04-18 2017-01-03 삼진제약주식회사 레바미피드 또는 이의 전구체를 포함하는 안구건조증의 예방 또는 치료를 위한 경구용 약제학적 조성물
US20160114048A1 (en) * 2013-05-16 2016-04-28 Universiteit Antwerpen Thermolabile drug release formulation
TWI697337B (zh) * 2013-08-07 2020-07-01 學校法人近畿大學 奈米粒子或奈米粒子組成物之製造方法，及支架或球囊導管之製造方法
CN104586762A (zh) * 2014-04-11 2015-05-06 广州仁恒医药科技有限公司 含有瑞巴派特的药物组合物及其制备方法
JP6854587B2 (ja) * 2015-04-17 2021-04-07 ロート製薬株式会社 医薬製剤
KR101718733B1 (ko) * 2015-08-21 2017-03-22 국제약품 주식회사 레바미피드의 가용화 방법 및 이에 의해 제조된 안구건조증 치료용 액제
KR20170039347A (ko) 2015-10-01 2017-04-11 삼진제약주식회사 레바미피드를 함유하는 신규한 점안 조성물 및 이의 제조방법
KR102307958B1 (ko) 2015-10-01 2021-10-05 삼진제약주식회사 레바미피드를 함유하는 신규한 점안 조성물 및 이의 제조방법
JP6732441B2 (ja) * 2015-12-11 2020-07-29 ロート製薬株式会社 局所粘膜適用水性組成物
KR101840256B1 (ko) * 2017-09-21 2018-03-21 대우제약 주식회사 레바미피드를 함유하는 새로운 안구건조증 치료용 점안 조성물 및 이의 가용화 및 안정화 방법
KR101923519B1 (ko) 2018-06-26 2019-02-27 대우제약 주식회사 레바미피드를 함유하는 안구 건조증 치료용 수용성 다회용 점안제 조성물 및 이의 가용화 및 안정화 방법
KR20200019451A (ko) 2018-08-14 2020-02-24 대우제약 주식회사 레바미피드를 함유하는 안구 건조증 치료용 수용성 다회용 점안제 조성물 및 이의 가용화 및 안정화 방법
KR102615076B1 (ko) * 2021-07-14 2023-12-19 대우제약 주식회사 안정한 레바미피드 점안제의 대용량 제조 방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50121414A (ko) 1974-02-18 1975-09-23
JPS55139319A (en) 1979-04-13 1980-10-31 Furointo Sangyo Kk Activation of drug soluble in alkali and acid
JP2808378B2 (ja) * 1991-03-27 1998-10-08 武田薬品工業株式会社 水性懸濁液剤の製造法
WO1992017174A1 (en) 1991-03-27 1992-10-15 Senju Pharmaceutical Co., Ltd. Process for preparing aqueous suspension
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5716642A (en) 1995-01-10 1998-02-10 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
JP3093661B2 (ja) * 1995-10-12 2000-10-03 大塚製薬株式会社 眼疾患治療剤
AR004214A1 (es) * 1995-10-12 1998-11-04 Otsuka Pharma Co Ltd Una preparación de gotas oftálmicas para la cura de enfermedades oftálmicas
JPH09301855A (ja) * 1996-05-13 1997-11-25 Fuairudo Kk 健康用部材
KR20010012188A (ko) 1997-05-14 2001-02-15 요시다 쇼지 재분산성이 양호한 수성 현탁액제
JP3402195B2 (ja) * 1997-05-14 2003-04-28 千寿製薬株式会社 再分散性の良い水性懸濁液剤
GB9810859D0 (en) * 1998-05-20 1998-07-22 Zeneca Ltd Crystallisation process
EP1407785A4 (en) * 2001-06-14 2009-12-02 Otsuka Pharma Co Ltd MEDICAL COMPOSITIONS

Also Published As

Publication number Publication date
HK1112718A1 (en) 2008-09-12
US20160101183A1 (en) 2016-04-14
AR108955A2 (es) 2018-10-10
JP4934587B2 (ja) 2012-05-16
RU2007122392A (ru) 2008-12-20
WO2006052018A1 (en) 2006-05-18
AU2005302908B2 (en) 2011-03-31
US9533052B2 (en) 2017-01-03
CA2584017C (en) 2013-08-27
EP1812000A4 (en) 2012-08-08
EP1812000A1 (en) 2007-08-01
JP2012092139A (ja) 2012-05-17
JP2008519759A (ja) 2008-06-12
CA2584017A1 (en) 2006-05-18
CN100594901C (zh) 2010-03-24
MY152867A (en) 2014-11-28
BRPI0518928A2 (pt) 2008-12-16
TWI363626B (en) 2012-05-11
AU2005302908A1 (en) 2006-05-18
TW200621252A (en) 2006-07-01
MX2007005782A (es) 2007-07-19
KR101271959B1 (ko) 2013-06-10
US9211254B2 (en) 2015-12-15
AR052779A1 (es) 2007-04-04
JP2014077012A (ja) 2014-05-01
US20070287729A1 (en) 2007-12-13
CN101056636A (zh) 2007-10-17
KR20070092965A (ko) 2007-09-14
RU2398585C2 (ru) 2010-09-10

Similar Documents

Publication Publication Date Title
SG156692A1 (en) Aqueous ophthalmic suspension of crystalline rebamipide
TW200606162A (en) Pyrazolopyridine derivatives
WO2004100881A3 (en) Preparation and use of aryl alkyl acid derivatives for the treatment of obesity
EP2340821A4 (en) PROPHYLAXIS AGENTS / ADULTS OF ADULT DISEASES WITH 5-AMINOLEVULINIC ACID, A 5-AMINOLEVULIC ACID DERIVATIVE OR 5-AMINOLEVULIC ACID SALT OR 5-AMINOLEVULIC ACID DERIVATIVE AS AN ACTIVE SUBSTANCE
WO2005013892A3 (en) Hydrolytically-resistant boron-containing therapeutics and methods of use
WO2006067165A3 (en) Indolidone derivatives for the treatment or prevention of fibrotic diseases
MY142067A (en) Xanthine derivatives as selective hm74a agonists, processes for the manufacture of said derivatives, formulations comprising these derivatives, and their use in the treatment of diseases where under-activation of the hm74a receptor contributes to the disease
MA33509B1 (fr) Dérivés de l'oxazine et leur utilisation dans le traitement de troubles neurologiques
WO2007096885A3 (en) Formulations containing a non-oxidative biocide and a source of active halogen and use thereof in water treatment
HK1087398A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
UA85559C2 (en) Aminobenzophenone compounds
MX2009005413A (es) Formas cristalinas del acido zoledronico.
PT1771178E (pt) Utilização de k-252a e de inibidores de quinase para a prevenção ou o tratamento de patologias associadas a hmgb1
WO2012048129A3 (en) Inhibitors of polo-like kinase
MXPA04006031A (es) Compuestos para el tratamiento de trastornos inflamatorios.
WO2009154304A3 (en) A pharmaceutical composition comprising rebamipide
IL176914A0 (en) Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, method for the production thereof and their use as medicaments
UY29859A1 (es) Derivados de 1-amino-isiquinolina,su preparación y su aplicación terapéutica
HK1106246A1 (en) S-tenatoprazole monohydrated sodium salt and the use thereof in therapy s-
UA95780C2 (en) Xanthine derivatives as selective hm74a agonists
WO2005110413A3 (en) Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions
EA200701797A1 (ru) Соли окаперидона и фармацевтические композиции, содержащие указанные соли
WO2006087147A3 (en) Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of fibromyalgia
EA200600115A1 (ru) Производные 2-аминобензойной кислоты
GB0504103D0 (en) Novel method